Pretreatment with the probiotic VSL#3 delays transition from inflammation to dysplasia in a rat model of colitis-associated cancer

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 301, Issue 6, 2011, Pages

  Appleyard, Caroline B ^a   Cruz, Myrella L ^a   Isidro, Angel A ^a   Arthur, Janelle C ^b   Jobin, Christian ^b   de Simone, Claudio ^c  

^a PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Animal model; Colon cancer

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE SPHINGOMYELINASE; ANGIOSTATIN; BACTERIAL DNA; BACTERIAL RNA; ENDOSTATIN; RNA 16S; SPHINGOMYELIN PHOSPHODIESTERASE; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; VSL3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL FLORA; BACTERIAL GENE; CANCER PREVENTION; CELL PROLIFERATION; CHRONIC DISEASE; COLITIS; COLON CARCINOGENESIS; COLON DYSPLASIA; COLON FLORA; COLON INJURY; COLORECTAL CARCINOMA; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; GASTROINTESTINAL DYSPLASIA; HISTOPATHOLOGY; MALE; MICROBIAL COMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPECIES COMPOSITION;

ALKALINE PHOSPHATASE; ANGIOSTATINS; ANIMALS; BIFIDOBACTERIUM; CHRONIC DISEASE; COLITIS; COLON; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; ENDOSTATINS; LACTOBACILLUS; MALE; METAGENOME; PRECANCEROUS CONDITIONS; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCITRIOL; STREPTOCOCCUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 82455192857     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00167.2011     Document Type: Article

References (55)

1. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, Guillen J, Krutzsch M, Batta AK, Salen G, Fales L, Koonce K, Parish D, Clouser M, Roe D, Lance P, Phoenix and Tucson Gastroenterologist Networks. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 97: 846-853, 2005.
2. Appleyard CB, Morales M, Santiago C. Chronic inflammation alters the contribution of neurokinin receptor subtypes to epithelial function in rat colon. Dig Dis Sci 53: 220-228, 2008.
3. Appleyard CB, Wallace JL. Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol Gastrointest Liver Physiol 269: G119-G125, 1995.
4. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854-862, 2001.
5. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100: 1539-1546, 2005.
6. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfey VL, Doetschman T, Dove WF, Pitot HC, Halberg RB, Itzkowitz SH, Groden J, Coffey R. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 124: 762-777, 2003.
7. Capurso G, Marignani M, Delle Fave G. Probiotics and the incidence of colorectal cancer: when evidence is not evident. Dig Liver Dis 38, Suppl 2: S277-S282, 2006.
8. Davis CD, Milner JA. Gastrointestinal microflora, food components and colon cancer prevention. J Nutr Biochem 20: 743-752, 2009.
9. Deng X, Tolstanova G, Khomenko T, Chen L, Tarnawski A, Szabo S, Sandor Z. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine. J Pharmacol Exp Ther 331: 1071-1078, 2009.
10. Di Marzio L, Di Leo A, Cinque B, Fanini D, Agnifili A, Berloco P, Linsalata M, Lorusso D, Barone M, De Simone C, Cifone MG. Detection of alkaline sphingomyelinase activity in human stool: proposed role as a new diagnostic and prognostic marker of colorectal cancer. Cancer Epidemiol Biomarkers Prev 14: 856-862, 2005.
11. Duan RD. Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim Biophys Acta 1761: 281-291, 2006.
12. Ewaschuk JB, Walker JW, Diaz H, Madsen KL. Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. J Nutr 136: 1483-1487, 2006.
13. Farraye FA, Odze RD, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138: 746-774, 2010.
14. Fenoglio-Preiser CM, Noffsinger AE, Stemmermann GN, Lantz PE, Listrom MB, Rilke FO. Inflammatory bowel disease. In: Gastrointestinal Pathology, an Atlas and Text, second ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999, p. 631-716.
15. Fitzpatrick LR, Hertzog KL, Quatse AL, Koltun WA, Small JS, Vrana K. Effects of the probiotic formulation VSL#3 on colitis in weanling rats. J Pediatr Gastroenterol Nutr 44: 561-570, 2007.
16. Fukata M, Abreu MT. Microflora in colorectal cancer: a friend to fear. Nat Med 16: 639-641, 2010.
17. Gionchetti P, Rizzello F, Morselli C, Poggioli G, Tambasco R, Calabrese C, Brigidi P, Vitali B, Straforini G, Campieri M. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 50: 2075-2082, 2007.
18. Hertervig E, Nilsson A, Bjork J, Hultkrantz R, Duan RD. Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity: a key factor to the unrestrained cell proliferation. Br J Cancer 81: 232-236, 1999.
19. Hertervig E, Nilsson A, Nyberg L, Duan RD. Alkaline sphingomyelinase activity is decreased in human colorectal carcinoma. Cancer 79: 448-453, 1997.
20. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 20: CD001176, 2010.
21. Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, Turner J, Fedorak R, Madsen K. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 15: 760-768, 2009.
22. Ingraham BA, Bragdon B, Nohe A. Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 24: 139-149, 2008.
23. Itzkowitz SH. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol Clin North Am 35: 553-571, 2006.
24. Kong J, Zhang Z, Musch MW, Ning G, Sun J, Hart J, Bissonnette M, Li YC. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 294: G208-G216, 2008.
25. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 31: 1-20, 2002.
26. López-Posadas R, González R, Ballester I, Martínez-Moya P, Romero- Calvo I, Suárez MD, Zarzuelo A, Martínez-Augustin O, Sánchez de Medina F. Tissue-nonspecific alkaline phosphatase is activated in enterocytes by oxidative stress via changes in glycosylation. Inflamm Bowel Dis 17: 543-556, 2011.
27. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591, 2001.
28. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104: 437-443, 2009.
29. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18: 1-5, 2003.
30. Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, Stagg AJ, Knight SC. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis 16: 1286-1298, 2010.
31. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA 107: 454-459, 2010.
32. Pousa ID, Algaba A, Linares PM, Sanz-Cameno P, Maté J, Moreno- Otero R, Bermejo F, Gisbert JP. Corticosteroids modulate angiogenic soluble factors in ulcerative colitis patients. Dig Dis Sci 56: 871-879, 2010.
33. Pousa ID, Maté J, Gisbert JP. Angiogenesis in inflammatory bowel disease. Eur J Clin Invest 38: 73-81, 2008.
34. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis 14: 662-668, 2008.
35. Rafter J. The effects of probiotics on colon cancer development. Nutr Res Rev 17: 277-284, 2004.
36. Reiff C, Delday M, Rucklidge G, Reid M, Duncan G, Wohlgemuth S, Hörmannsperger G, Loh G, Blaut M, Collie-Duguid E, Haller D, Kelly D. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 15: 1721-1736, 2009.
37. Sanchez de Medina F, Martinez-Augustin O, Gonzalez R, Ballester I, Nieto A, Gálvez J, Zarzuelo A. Induction of alkaline phosphatase in the inflamed intestine: a novel pharmacological target for inflammatory bowel disease. Biochem Pharmacol 68: 2317-2326, 2004.
38. Santiago C, Pagán B, Isidro AA, Appleyard CB. Prolonged chronic inflammation progresses to dysplasia in a novel rat model of colitisassociated colon cancer. Cancer Res 67: 10766-10773, 2007.
39. Schwiertz A, Jacobi M, Frick JS, Richter M, Rusch K, Köhler H. Microbiota in pediatric inflammatory bowel disease. J Pediatr 157: 240-244, 2010.
40. Sjöqvist U, Hertervig E, Nilsson A, Duan RD, Ost A, Tribukait B, Löfberg R. Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis 8: 258-263, 2002.
41. Soo I, Madsen KL, Tejpar Q, Sydora BC, Sherbaniuk R, Cinque B, Di Marzio L, Cifone MG, Desimone C, Fedorak RN. VSL#3 probiotic upregulates intestinal mucosal alkaline sphingomyelinase and reduces inflammation. Can J Gastroenterol 22: 237-242, 2008.
42. Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7: 1202-1209, 2009.
43. Tuin A, Poelstra K, de Jager-Krikken A, Bok L, Raaben W, Velders MP, Dijkstra G. Role of alkaline phosphatase in colitis in man and rats. Gut 58: 379-387, 2009.
44. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105: 2218-2227, 2010.
45. Ulisse S, Gionchetti P, D'alo S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 96: 2691-2699, 2001.
46. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 140: 1807-1816, 2011.
47. Ullman T, Odze R, Farraye FA. Diagnosis and management of dysplasia in patients with ulcerative colitis and Crohn's disease of the colon. Inflamm Bowel Dis 15: 630-638, 2009.
48. Uronis JM, Arthur JC, Keku T, Fodor A, Carroll IM, Cruz ML, Appleyard CB, Jobin C. Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis 17: 289-297, 2011.
49. Uronis JM, Jobin C. Microbes and colorectal cancer: is there a relationship? Curr Oncol 16: 22-24, 2009.
50. Viscido A, Bagnardi V, Sturniolo GC, Annese V, Frieri G, D'Arienzo A, Papi C, Riegler G, Corrao G, Caprilli R. GISC: Italian Group for the Study of the Colon and Rectum. Survival and causes of death in Italian patients with ulcerative colitis, a GISC nationwide study. Dig Liver Dis 33: 686-692, 2001.
51. Wada K, Tanaka H, Maeda K, Inoue T, Noda E, Amano R, Kubo N, Muguruma K, Yamada N, Yashiro M, Sawada T, Nakata B, Ohira M, Hirakawa K. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 22: 1021-1025, 2009.
52. Wahle KW, Heys SD, Rotondo D. Conjugated linoleic acids: are they beneficial or detrimental to health? Prog Lipid Res 43: 553-587, 2004.
53. Wang X, O'Gorman MR, Bu HF, Koti V, Zuo XL, Tan XD. Probiotic preparation VSL#3 alters the distribution and phenotypes of dendritic cells within the intestinal mucosa in C57BL/10J mice. J Nutr 139: 1595-1602, 2009.
54. Waterhouse JC, Perez TH, Albert PJ. Reversing bacteria-induced vitamin D receptor dysfunction is key to autoimmune disease. Ann NY Acad Sci 1173: 757-765, 2009.
55. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 22: 783-788, 2005.